We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





LumiraDx Point of Care COVID-19 Antigen Test Detects All Major Global SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 28 Jun 2021
Print article
Image: LumiraDx SARS-CoV-2 Ag Test (Photo courtesy of LumiraDx)
Image: LumiraDx SARS-CoV-2 Ag Test (Photo courtesy of LumiraDx)
LumiraDx (London, UK) has confirmed that its LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants, including the Alpha, Beta, Gamma, Delta and Epsilon variants.

SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time. While some new variants may emerge and disappear, or be clinically inconsequential, others emerge and dominate and have been detected globally during this pandemic. LumiraDx is actively monitoring how its SARS-CoV-2 Antigen test performs against new variants of the SARS-CoV-2 virus. The company's in-house evaluation is carried out using in silico analysis and direct testing with either recombinant nucleocapsid protein or viral isolates.

The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants. Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein. Antibodies typically recognize 8-15 amino acid target sequences which are equivalent to 24-45 nucleotide sequences. Thus, single nucleic acid point mutations are not likely to affect the performance of the LumiraDx SARS-CoV-2 Ag Test. Furthermore, mutations outside of the nucleocapsid viral coding region (ex Spike protein) are also unlikely to affect the assay performance.

"Since the COVID-19 virus emerged early last year, we have learned an extraordinary amount about how this virus spreads and importantly, how it can mutate," said Nigel Lindner, PhD, LumiraDx's Chief Innovation Officer. "We know that testing is a critical component in the monitoring and controlling of the spread of the virus. This becomes even more important with the emergence of new, and unfamiliar variants. We are committed not only to ensuring we are following all guidelines to monitor for these variants of concern, but also to sharing this data and our monitoring program process with our customers."

Related Links:
LumiraDx

Gold Member
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
Automated Blood Typing System
IH-500 NEXT
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.